(1S,2S)-Bortezomib |
Katalog-Nr.GC62193 |
(1S,2S)-Bortezomib ist ein Enantiomer von Bortezomib. Bortezomib ist ein zellgÄngiger, reversibler und selektiver Proteasom-Inhibitor und hemmt wirksam das 20S-Proteasom (Ki von 0,6 nM), indem es auf einen Threoninrest abzielt. Bortezomib unterbricht den Zellzyklus, induziert Apoptose und hemmt NF-κB. Bortezomib ist ein Krebsmittel und der erste therapeutische Proteasom-Inhibitor, der beim Menschen eingesetzt wird.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1132709-14-8
Sample solution is provided at 25 µL, 10mM.
(1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a cell-permeable, reversible, and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki of 0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is an anti-cancer agent and the first therapeutic proteasome inhibitor to be used in humans[1][2][3].
[1]. Kamalzadeh Z, et al. Determination of Bortezomib in API Samples Using HPLC: Assessment of Enantiomeric and Diastereomeric Impurities. J Chromatogr Sci. 2017 Aug 1;55(7):697-705.
[2]. Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22.
[3]. Shahshahan MA, et al. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastaticmelanoma: basic and clinical aspects. Am J Cancer Res. 2011;1(7):913-24.
Average Rating: 5
(Based on Reviews and 11 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *